Previous 10 | Next 10 |
Allogene Therapeutics ( ALLO ) has a pipeline full of immunotherapy products it is developing to treat different types of cancer. Specifically, its platform relies on allogeneic CAR-T therapies. The latest partnership involves Notch Therapeutics and its own technology platform to treat can...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two ...
The following companies have filed for mixed shelf offerings: More news on: Nephros, Inc., Voyager Therapeutics, Inc., Allogene Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, today announced that it will ...
Image source: The Motley Fool. Allogene Therapeutics Inc (NASDAQ: ALLO) Q3 2019 Earnings Call Nov 05, 2019 , 8:30 a.m. ET Operator Continue reading
Allogene Therapeutics, Inc. (ALLO) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - Executive Vice President of Research and Devel...
Allogene Therapeutics ( ALLO -3.1% ) will collaborate with privately held Notch Therapeutics to develop AlloCAR T therapies using induced pluripotent stem cells (iPSC) to create gene-edited T cells instead of using mature donor T cells. The approach, leveraging Notch's Engineered Thym...
Allogene Therapeutics (NASDAQ: ALLO ): Q3 GAAP EPS of -$0.50 beats by $0.05 . More news on: Allogene Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM) Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) with Data Expected in First Half of 2020 Entered into Exclusive Collaboration with Notch Th...
Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales SOUT...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...